id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
8435665_3 | Thus, the eosinophilia myalgia syndrome can be associated with parenteral tryptophan administration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[47]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"eosinophilia myalgia syndrome\"]], \"start\": [[10]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"parenteral tryptophan\"]], \"start\": [[63]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"tryptophan\"]], \"start\": [[74]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"parenteral\"]], \"start\": [[63]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"can be\"]], \"start\": [[40]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
3790438_1 | Generalized pustular psoriasis precipitated by trazodone in the treatment of depression. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"precipitated\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"trazodone\"]], \"start\": [[47]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"depression\"]], \"start\": [[77]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"trazodone\"]], \"start\": [[47]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Generalized pustular psoriasis\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
15224368_3 | We report a case of Sweet's syndrome in association with sargramostim treatment following chemotherapy for acute myelogenous leukemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"association\"]], \"start\": [[40]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"sargramostim treatment following chemotherapy\"]], \"start\": [[57]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"sargramostim\"]], \"start\": [[57]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[90]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"acute myelogenous leukemia\"]], \"start\": [[107]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"Sweet's syndrome\"]], \"start\": [[20]], \"entity_id\": [\"T3\"]}}"
}
]
}
] |
10772434_2 | This regimen could prove useful for other patients who develop hypersensitivity reactions to carboplatin and allow therapy to continue. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develop\"]], \"start\": [[55]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"hypersensitivity reactions\"]], \"start\": [[63]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"carboplatin\"]], \"start\": [[93]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"carboplatin\"]], \"start\": [[93]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[42]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"could\"]], \"start\": [[13]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
12150593_2 | We present a neonate with a seizure disorder who acutely developed pupillary mydriasis secondary to lidocaine overdose. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[57]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a neonate with a seizure disorde\"]], \"start\": [[11]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"neonate\"]], \"start\": [[13]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"pupillary mydriasis\"]], \"start\": [[67]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"lidocaine overdose\"]], \"start\": [[100]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"lidocaine\"]], \"start\": [[100]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"overdose\"]], \"start\": [[110]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"seizure disorder\"]], \"start\": [[28]], \"entity_id\": [\"T12\"]}}, \"Severity\": {\"text\": [[\"acutely\"]], \"start\": [[49]], \"entity_id\": [\"T5\"], \"value\": \"High\"}}"
}
]
}
] |
18691992_2 | Based on the Naranjo algorithm, the adverse reaction observed was probably related to the hydroxyurea treatment (score = 6); however, the hydroxyurea chemotherapy could not be discontinued because of the myeloproliferative disorder. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[75]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"hydroxyurea chemotherapy\"]], \"start\": [[138]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"hydroxyurea\"], [\"hydroxyurea\"]], \"start\": [[90], [138]], \"entity_id\": [\"T6\", \"T7\"]}, \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[150]], \"entity_id\": [\"T4\"]}}, \"Effect\": {\"text\": [[\"myeloproliferative disorder\"]], \"start\": [[204]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"probably\"]], \"start\": [[66]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
7673653_2 | Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors (SSRIs), i.e. fluoxetine and sertraline, have been previously reported in patients with depression and obsessive-compulsive disorder (OCD). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced by\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Extrapyramidal side effects\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"some selective serotonin reuptake inhibitors (SSRIs), i.e. fluoxetine and sertraline\"]], \"start\": [[39]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"depression\"], [\"obsessive-compulsive disorder (OCD)\"]], \"start\": [[172], [187]], \"entity_id\": [\"T8\", \"T9\"]}, \"Drug\": {\"text\": [[\"fluoxetine\"], [\"sertraline\"], [\"serotonin reuptake inhibitors\"]], \"start\": [[98], [113], [54]], \"entity_id\": [\"T10\", \"T11\", \"T12\"]}}, \"Subject\": {\"text\": [[\"patients with depression and obsessive-compulsive disorder (OCD)\"]], \"start\": [[158]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
9291634_6 | Ten-17 days after receiving chemotherapy, five patients (4 males and 1 female) with acute lymphoblastic leukemia developed incapacitating myalgias in neck, thighs and arms. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[113]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"five patients (4 males and 1 female) with acute lymphoblastic leukemia\"]], \"start\": [[42]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"five\"]], \"start\": [[42]], \"entity_id\": [\"T12\"]}, \"Gender\": {\"text\": [[\"4 males and 1 female\"]], \"start\": [[57]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"incapacitating myalgias in neck, thighs and arms\"]], \"start\": [[123]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Ten-17 days after receiving chemotherapy\"]], \"start\": [[0]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"acute lymphoblastic leukemia\"]], \"start\": [[84]], \"entity_id\": [\"T14\"]}, \"Time_elapsed\": {\"text\": [[\"Ten-17 days\"]], \"start\": [[0]], \"entity_id\": [\"T15\"]}, \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[28]], \"entity_id\": [\"T16\"]}}}"
}
]
}
] |
21597286_2 | We report a case of a potential drug-drug interaction in a woman treated by a first injection of high-dose methotrexate for a T-lymphoblastic lymphoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[65]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a woman\"]], \"start\": [[57]], \"entity_id\": [\"T6\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[59]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"a first injection of high-dose methotrexate\"]], \"start\": [[76]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"a T-lymphoblastic lymphoma\"]], \"start\": [[124]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"injection\"]], \"start\": [[84]], \"entity_id\": [\"T11\"]}, \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[97]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[107]], \"entity_id\": [\"T13\"]}}, \"Speculated\": {\"text\": [[\"potential\"]], \"start\": [[22]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
16791713_4 | We conclude that myocardial infarction may develop in patients treated with high-dose glucocorticoids for Graves' ophthalmopathy, and increased blood pressure may herald this complication. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develop\"]], \"start\": [[43]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"myocardial infarction\"], [\"increased blood pressure\"]], \"start\": [[17], [134]], \"entity_id\": [\"T3\", \"T6\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[54]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"high-dose glucocorticoids\"]], \"start\": [[76]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"glucocorticoids\"]], \"start\": [[86]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[76]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"Graves' ophthalmopathy\"]], \"start\": [[106]], \"entity_id\": [\"T10\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[39]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
19798640_1 | A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[67]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"primary central nervous system lymphoma (PCNSL)\"]], \"start\": [[77]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"21 doses of natalizumab monotherapy\"]], \"start\": [[147]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"relapsing-remitting multiple sclerosis (MS)\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}, \"Dosage\": {\"text\": [[\"21 doses\"]], \"start\": [[147]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"natalizumab\"]], \"start\": [[159]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"40-year-old man with relapsing-remitting multiple sclerosis (MS)\"]], \"start\": [[2]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"40-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
11816261_4 | Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[19]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"selective serotonin reuptake-inhibitors-metoclopramide interaction\"]], \"start\": [[29]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"metoclopramide\"], [\"selective serotonin reuptake-inhibitors\"]], \"start\": [[69], [29]], \"entity_id\": [\"T7\", \"T8\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[84]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"metoclopramide\"], [\"selective serotonin reuptake-inhibitors\"]], \"start\": [[69], [29]], \"entity_id\": [\"T7\", \"T8\"]}}]}, \"Effect\": {\"text\": [[\"Serotonin syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
7937287_10 | This is the first reported case of suspected DIAN due to cefuroxime. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due to\"]], \"start\": [[50]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"DIAN\"]], \"start\": [[45]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"cefuroxime\"]], \"start\": [[57]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"cefuroxime\"]], \"start\": [[57]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"first reported case\"]], \"start\": [[12]], \"entity_id\": [\"T10\"]}, \"Speculated\": {\"text\": [[\"suspected\"]], \"start\": [[35]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
7995508_2 | We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[38]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a cae\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"decongestant containing PPA\"]], \"start\": [[57]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"PPA\"]], \"start\": [[81]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"paranoid psychosis\"]], \"start\": [[19]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
17133571_1 | Liver transplantation for fulminant hepatitis related to nevirapine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[46]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Liver transplantation for fulminant hepatitis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"nevirapine therapy\"]], \"start\": [[57]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"nevirapine\"]], \"start\": [[57]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
11414270_2 | OBJECTIVE: To report a case of fatal hyperkalemia owing to succinylcholine administration in a patient with mucositis secondary to chemotherapy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"owing\"]], \"start\": [[50]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"a patient with mucositis secondary to chemotherapy\"]], \"start\": [[93]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"succinylcholine administration\"]], \"start\": [[59]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"mucositis\"]], \"start\": [[108]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"succinylcholine\"]], \"start\": [[59]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"hyperkalemia\"]], \"start\": [[37]], \"entity_id\": [\"T9\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[31]], \"entity_id\": [\"T14\"], \"value\": \"High\"}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary\"]], \"start\": [[118]], \"entity_id\": [\"T18\"]}, \"Treatment\": {\"text\": [[\"chemotherapy\"]], \"start\": [[131]], \"entity_id\": [\"T22\"], \"Drug\": {\"text\": [[\"chemotherapy\"]], \"start\": [[131]], \"entity_id\": [\"T19\"]}}, \"Effect\": {\"text\": [[\"mucositis\"]], \"start\": [[108]], \"entity_id\": [\"T21\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[93]], \"entity_id\": [\"T20\"]}}"
}
]
}
] |
8835752_3 | We describe a case of prolonged terbinafine-induced cholestatic liver disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[44]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"prolonged terbinafine\"]], \"start\": [[22]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"terbinafine\"]], \"start\": [[32]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[12]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"cholestatic liver disease\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
10707759_3 | We describe a case of interstitial hypoxaemiant pneumonitis probably related to flecainide in a patient with the LEOPARD syndrome, a rare congenital disorder. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[69]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"interstitial hypoxaemiant pneumonitis\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"flecainide\"]], \"start\": [[80]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"flecainide\"]], \"start\": [[80]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"LEOPARD syndrome\"]], \"start\": [[113]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"a patient with the LEOPARD syndrome\"]], \"start\": [[94]], \"entity_id\": [\"T4\"]}, \"Speculated\": {\"text\": [[\"probably\"]], \"start\": [[60]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
7718983_4 | This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH-receptor autoantibodies, and then the occurrence of Graves' hyperthyroidism during IFN therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurrence\"]], \"start\": [[135]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Graves' hyperthyroidism\"]], \"start\": [[149]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"IFN therapy\"]], \"start\": [[180]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"IFN\"]], \"start\": [[180]], \"entity_id\": [\"T6\"]}}, \"Subject\": {\"text\": [[\"This case\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
3405528_2 | Halothane hepatitis and prompt resolution with methionine therapy: case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"resolution\"]], \"start\": [[31]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"methionine\"]], \"start\": [[47]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"Halothane hepatitis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"methionine\"]], \"start\": [[47]], \"entity_id\": [\"T6\"]}}, \"Subject\": {\"text\": [[\"case\"]], \"start\": [[67]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
11706664_2 | This report describes an unexpected drug-induced hepatitis in a previously healthy young woman exposed to 2 doses of amodiaquine and artesunate. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"exposed\"]], \"start\": [[95]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"hepatitis\"]], \"start\": [[49]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a previously healthy young woman\"]], \"start\": [[62]], \"entity_id\": [\"T5\"], \"Gender\": {\"text\": [[\"young\"], [\"woman\"]], \"start\": [[83], [89]], \"entity_id\": [\"T9\", \"T10\"]}}, \"Treatment\": {\"text\": [[\"2 doses of amodiaquine and artesunate\"]], \"start\": [[106]], \"entity_id\": [\"T6\"], \"Dosage\": {\"text\": [[\"2 doses\"]], \"start\": [[106]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"amodiaquine\"], [\"artesunate\"]], \"start\": [[117], [133]], \"entity_id\": [\"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[129]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"amodiaquine\"], [\"artesunate\"]], \"start\": [[117], [133]], \"entity_id\": [\"T12\", \"T13\"]}}]}, \"Speculated\": {\"text\": [[\"unexpected\"]], \"start\": [[25]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
3680913_1 | It was restarted 6 weeks later, and 10 weeks after that, the patient presented with fulminant hepatic failure, which resolved rapidly after cessation of nicotinic acid therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presented\"]], \"start\": [[69]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"fulminant hepatic failure\"]], \"start\": [[84]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"10 weeks after\", \"nicotinic acid\"]], \"start\": [[36, 153]], \"entity_id\": [\"T4\"], \"Time_elapsed\": {\"text\": [[\"10 weeks after\"]], \"start\": [[36]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"nicotinic acid\"]], \"start\": [[153]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[57]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
9366852_4 | We describe a patient with the antiphospholipid syndrome who had skin necrosis develop from low-molecular weight heparin therapy at sites distant from injection sites. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develop\"]], \"start\": [[79]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"skin necrosis\"]], \"start\": [[65]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"low-molecular weight heparin therapy at sites distant from injection sites\"]], \"start\": [[92]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"antiphospholipid syndrome\"]], \"start\": [[31]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"low-molecular weight heparin\"]], \"start\": [[92]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"injection\"]], \"start\": [[151]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"a patient with the antiphospholipid syndrome\"]], \"start\": [[12]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
18022748_11 | While CYP form induction by Pyrethrins, Phenobarbital and related compounds can be associated with liver and thyroid gland tumour formation in rodents, epidemiological data for Phenobarbital suggests that such effects do not occur in humans. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induction\"]], \"start\": [[15]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"Pyrethrins, Phenobarbital and related compounds\"]], \"start\": [[28]], \"entity_id\": [\"T14\"], \"Drug\": {\"text\": [[\"Pyrethrins\"], [\"Phenobarbital\"], [\"related compounds\"]], \"start\": [[28], [40], [58]], \"entity_id\": [\"T16\", \"T17\", \"T18\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[54]], \"entity_id\": [\"T19\"]}, \"Drug\": {\"text\": [[\"related compounds\"], [\"Phenobarbital\"], [\"Pyrethrins\"]], \"start\": [[58], [40], [28]], \"entity_id\": [\"T18\", \"T17\", \"T16\"]}}]}, \"Effect\": {\"text\": [[\"liver and thyroid gland tumour formation in rodents\"]], \"start\": [[99]], \"entity_id\": [\"T15\"]}, \"Negated\": {\"text\": [[\"do not occur\"]], \"start\": [[218]], \"entity_id\": [\"T20\"], \"value\": true}}"
}
]
}
] |
7416268_1 | Disulfiram encephalopathy as a cause of the catatonia syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[31]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Disulfiram\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Disulfiram\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"catatonia syndrome\", \"encephalopathy\"]], \"start\": [[44, 11]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
7653281_2 | Little has been studied of the adverse effects of the exposure of the liver to the interaction of ethanol with its congeners and acetaldehyde, coexisting in the contents of alcoholic beverages. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[83]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"adverse effects of the exposure of the liver\"]], \"start\": [[31]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"ethanol with its congeners and acetaldehyde\"]], \"start\": [[98]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"acetaldehyde\"], [\"ethanol\"]], \"start\": [[129], [98]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[83]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"ethanol\"], [\"acetaldehyde\"]], \"start\": [[98], [129]], \"entity_id\": [\"T10\", \"T9\"]}}]}}"
}
]
}
] |
22735246_1 | Fatal serotonin syndrome precipitated by oxcarbazepine in a patient using an selective serotonin reuptake inhibitor. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"precipitated\"]], \"start\": [[25]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[6]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"oxcarbazepine\"]], \"start\": [[41]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"oxcarbazepine\"]], \"start\": [[41]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[58]], \"entity_id\": [\"T9\"]}, \"Severity\": {\"text\": [[\"Fatal\"]], \"start\": [[0]], \"entity_id\": [\"T10\"], \"value\": \"Medium\"}}"
}
]
}
] |
11568758_2 | This eruption emerged after 1 month of therapy with salsalate, persisted for as long as salsalate was administered, and cleared within 3 weeks of discontinuing the medication. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"emerged\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"eruption\"]], \"start\": [[5]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"after 1 month of therapy with salsalate\"]], \"start\": [[22]], \"entity_id\": [\"T5\"], \"Time_elapsed\": {\"text\": [[\"1 month\"]], \"start\": [[28]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"salsalate\"]], \"start\": [[52]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
8969033_1 | A case report is presented concerning the administration of ketanserin in the treatment of pulmonary vasoconstriction and right ventricular failure following the infusion of protamine in a patient undergoing coronary artery bypass surgery and mitral valve replacement. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[148]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"infusion of protamine\", \"undergoing coronary artery bypass surgery and mitral valve replacement\"]], \"start\": [[162, 197]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"protamine\"]], \"start\": [[174]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"infusion\"]], \"start\": [[162]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[187]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"pulmonary vasoconstriction and right ventricular failure\"]], \"start\": [[91]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
10803790_7 | When cyanamide-treated alcoholics relapse into drinking, more severe inflammation develops in the liver. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develops\"]], \"start\": [[82]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"cyanamide\"]], \"start\": [[5]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"cyanamide\"]], \"start\": [[5]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"alcoholics\"]], \"start\": [[23]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"inflammation\"]], \"start\": [[69]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"cyanamide-treated alcoholics\"]], \"start\": [[5]], \"entity_id\": [\"T6\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[62]], \"entity_id\": [\"T10\"], \"value\": \"High\"}}"
}
]
}
] |
9256906_2 | Acute renal failure should be recognized as a potential complication of suramin treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[56]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Acute renal failure\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"suramin treatment\"]], \"start\": [[72]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"suramin\"]], \"start\": [[72]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"potential\"]], \"start\": [[46]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
8936932_2 | After induction of general anesthesia and administration of a standard dose of intravenous esmolol hydrochloride, her cardiac rhythm progressed to asystole. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"After\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"induction of general anesthesia and administration of a standard dose of intravenous esmolol hydrochloride\"]], \"start\": [[6]], \"entity_id\": [\"T3\"], \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[79]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"esmolol hydrochloride\"], [\"general anesthesia\"]], \"start\": [[91], [19]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[38]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"general anesthesia\"], [\"esmolol hydrochloride\"]], \"start\": [[19], [91]], \"entity_id\": [\"T10\", \"T9\"]}}]}, \"Subject\": {\"text\": [[\"her\"]], \"start\": [[114]], \"entity_id\": [\"T4\"], \"Gender\": {\"text\": [[\"her\"]], \"start\": [[114]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"asystole\"]], \"start\": [[147]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
2875665_1 | Exacerbation of schizophrenia associated with amantadine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[30]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"amantadine\"]], \"start\": [[46]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"amantadine\"]], \"start\": [[46]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Exacerbation of schizophrenia\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
10431414_2 | Priapism as a complication of heparin therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[14]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Priapism\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"heparin\"]], \"start\": [[30]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"heparin\"]], \"start\": [[30]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
1977935_1 | Torsades de pointes occurring in association with terfenadine use. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"association\"]], \"start\": [[33]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Torsades de pointes\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"terfenadine\"]], \"start\": [[50]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"terfenadine\"]], \"start\": [[50]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
10452772_5 | Protamine allergy as a complication of insulin hypersensitivity: A case report. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"insulin\"]], \"start\": [[39]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"insulin\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity\", \"Protamine allergy\"]], \"start\": [[47, 0]], \"entity_id\": [\"T3\"]}}"
}
]
}
] |
10524732_2 | We report a case of recurrent torsades de pointes following treatment with pentavalent antimonial drugs and amiodarone. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treatment with\"]], \"start\": [[60]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"pentavalent antimonial drugs and amiodarone\"]], \"start\": [[75]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"amiodarone\"], [\"pentavalent antimonial drugs\"]], \"start\": [[108], [75]], \"entity_id\": [\"T6\", \"T7\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[104]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"pentavalent antimonial drugs\"], [\"amiodarone\"]], \"start\": [[75], [108]], \"entity_id\": [\"T7\", \"T6\"]}}]}, \"Effect\": {\"text\": [[\"recurrent torsades de pointes\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
2038845_1 | This case presentation is of a patient who had the clinical appearance of epiglottitis, but actually had an oro-pharyngeal dystonic reaction to prochlorperazine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"had\"]], \"start\": [[101]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[29]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"prochlorperazine\"]], \"start\": [[144]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"prochlorperazine\"]], \"start\": [[144]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"clinical appearance of epiglottitis\", \"actually had an oro-pharyngeal dystonic reaction\"]], \"start\": [[51, 92]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19537383_1 | Localized dyskeratotic plaque with milia associated with sorafenib. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[41]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"sorafenib\"]], \"start\": [[57]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"sorafenib\"]], \"start\": [[57]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Localized dyskeratotic plaque with milia\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
7416268_2 | The authors describe a case of the catatonia syndrome associated with disulfiram therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[54]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"catatonia syndrome\"]], \"start\": [[35]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"disulfiram therapy\"]], \"start\": [[70]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"disulfiram\"]], \"start\": [[70]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
23624139_2 | Most of the clinical data on the safety profile of desmopressin (DDAVP), which is an effective treatment for both polyuric conditions and bleeding disorders, originate from studies on the tailoring of drug treatment, whereas few reports exist describing severe side effects secondary to drug-drug interaction. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[95]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"desmopressin (DDAVP)\"]], \"start\": [[51]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"desmopressin\"]], \"start\": [[51]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"polyuric conditions\"], [\"bleeding disorders\"]], \"start\": [[114], [138]], \"entity_id\": [\"T14\", \"T15\"]}}, \"Subject\": {\"text\": [[\"both polyuric conditions and bleeding disorders\"]], \"start\": [[109]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
7663030_12 | Propafenone's distribution, clearance, and structural similarity to propranolol contribute to its central nervous system effects. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"contribute\"]], \"start\": [[80]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Propafenone\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"propranolol\"], [\"Propafenone\"]], \"start\": [[68], [0]], \"entity_id\": [\"T8\", \"T7\"]}}, \"Effect\": {\"text\": [[\"central nervous system effects\"]], \"start\": [[98]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19423610_1 | Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium. | true | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[34]], \"entity_id\": [\"T11\"]}, \"Effect\": {\"text\": [[\"serotonin toxicity\", \"post-operative delirium\"]], \"start\": [[15, 145]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"co-administration of methylene blue and serotonin reuptake inhibitors\"]], \"start\": [[44]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"methylene blue\"], [\"serotonin reuptake inhibitors\"]], \"start\": [[65], [84]], \"entity_id\": [\"T9\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E1\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"co-administration\"]], \"start\": [[44]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"methylene blue\"], [\"serotonin reuptake inhibitors\"]], \"start\": [[65], [84]], \"entity_id\": [\"T9\", \"T12\"]}}]}}"
}
]
}
] |
19782276_9 | Cyclophosphamide-induced cardiotoxicity occurred, even though the patient had both shown normal cardiac function before high-dose chemotherapy and had received a lower dose of cyclophosphamide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[17]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Cyclophosphamide\", \"high-dose chemotherapy and had received a lower dose of cyclophosphamide\"]], \"start\": [[0, 120]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Cyclophosphamide\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}, \"Dosage\": {\"text\": [[\"lower dose\"]], \"start\": [[162]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"cardiotoxicity\"]], \"start\": [[25]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"the patient had both shown normal cardiac function\"]], \"start\": [[62]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
18707772_1 | A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for intracranial bleeding while receiving aspirin and clopidogrel. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[144]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"A 64 year old woman with previous history of coronary stenting\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"64 year old\"]], \"start\": [[2]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"intracranial bleeding\"]], \"start\": [[116]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"five days before\", \"aspirin and clopidogrel\"]], \"start\": [[63, 154]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"clopidogrel\"], [\"aspirin\"]], \"start\": [[166], [154]], \"entity_id\": [\"T11\", \"T12\"]}, \"Disorder\": {\"text\": [[\"coronary stenting\"]], \"start\": [[45]], \"entity_id\": [\"T14\"]}, \"Time_elapsed\": {\"text\": [[\"five days\"]], \"start\": [[63]], \"entity_id\": [\"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[162]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"aspirin\"], [\"clopidogrel\"]], \"start\": [[154], [166]], \"entity_id\": [\"T12\", \"T11\"]}}]}}"
}
]
}
] |
12324937_5 | METHODS: A case is presented of a 45-year-old woman on prolonged gemcitabine treatment for ovarian cancer who developed HUS and recovered after drug discontinuation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[110]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a 45-year-old woman\"]], \"start\": [[32]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"45-year-old\"]], \"start\": [[34]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[46]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"prolonged gemcitabine treatment\"]], \"start\": [[55]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"gemcitabine\"]], \"start\": [[65]], \"entity_id\": [\"T10\"]}, \"Duration\": {\"text\": [[\"prolonged\"]], \"start\": [[55]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"ovarian cance\"]], \"start\": [[91]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"HUS\"]], \"start\": [[120]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
889156_4 | A more serious development of adrenal insufficiency may occur upon the improper replacement of systemic steroids. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"replacement\"]], \"start\": [[80]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"development of adrenal insufficiency\"]], \"start\": [[15]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"systemic steroids\"]], \"start\": [[95]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"steroids\"]], \"start\": [[104]], \"entity_id\": [\"T9\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[52]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
1495728_2 | We describe a case of pneumonitis following local administration of methotrexate for nonsurgical termination of an ectopic pregnancy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[34]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[12]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"pneumonitis\"]], \"start\": [[22]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"local administration of methotrexate\"]], \"start\": [[44]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[68]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"ectopic pregnancy\"]], \"start\": [[115]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
14690166_2 | There is currently no consensus on the best treatment for unresectable hyaline-vascular variant or for multicentric Castleman's disease (MCD), because none of the reported regimens have consistently produced complete response or durable remission in the majority of patients In the present study, we report on the use of 2-CdA (2-chloro-deoxyadenosine) in three patients, two of them with MCD and one with unresectable hyaline-vascular type disease. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"use\"]], \"start\": [[314]], \"entity_id\": [\"T14\"]}, \"Subject\": {\"text\": [[\"one\"]], \"start\": [[397]], \"entity_id\": [\"T19\"], \"Population\": {\"text\": [[\"one\"]], \"start\": [[397]], \"entity_id\": [\"T13\"]}}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"use\"]], \"start\": [[314]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"2-CdA (2-chloro-deoxyadenosine)\"], [\"2-CdA (2-chloro-deoxyadenosine)\"]], \"start\": [[321], [321]], \"entity_id\": [\"T12\", \"T23\"], \"Drug\": {\"text\": [[\"2-CdA\"], [\"2-CdA\"]], \"start\": [[321], [321]], \"entity_id\": [\"T24\", \"T20\"]}, \"Disorder\": {\"text\": [[\"MCD\"], [\"unresectable hyaline-vascular type disease\"]], \"start\": [[389], [406]], \"entity_id\": [\"T17\", \"T22\"]}}, \"Subject\": {\"text\": [[\"two\"]], \"start\": [[372]], \"entity_id\": [\"T21\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[372]], \"entity_id\": [\"T16\"]}}}"
}
]
}
] |
19667003_1 | Carbamazepine-induced hyperammonemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[14]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Carbamazepine\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Carbamazepine\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"hyperammonemia\"]], \"start\": [[22]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
10803790_3 | Case 3: A 29-year-old female alcoholic complained of general fatigue and a slight fever after 1.5 years of abstinence with cyanamide treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complained\"]], \"start\": [[39]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"A 29-year-old female alcoholic\"]], \"start\": [[8]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"29-year-old\"]], \"start\": [[10]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"female\"]], \"start\": [[22]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"general fatigue and a slight fever\"]], \"start\": [[53]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"after 1.5 years of abstinence with cyanamide\"]], \"start\": [[88]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"alcoholic\"]], \"start\": [[29]], \"entity_id\": [\"T11\"]}, \"Duration\": {\"text\": [[\"1.5 years\"]], \"start\": [[94]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"cyanamide\"]], \"start\": [[123]], \"entity_id\": [\"T15\"]}}, \"Severity\": {\"text\": [[\"slight\"]], \"start\": [[75]], \"entity_id\": [\"T12\"], \"value\": \"Medium\"}}"
}
]
}
] |
10667036_1 | Caution is, therefore, needed to prevent undesired accumulation of TCA that may lead to protracted Cushing's syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"lead to\"]], \"start\": [[80]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"TCA\"]], \"start\": [[67]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"TCA\"]], \"start\": [[67]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"protracted Cushing's syndrome\"]], \"start\": [[88]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
7408538_2 | Unusual pigmentary changes associated with 5-fluorouracil therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[27]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Unusual pigmentary changes\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"5-fluorouracil\"]], \"start\": [[43]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"5-fluorouracil\"]], \"start\": [[43]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
9876812_4 | Syndrome of inappropriate antidiuretic hormone associated with vinorelbine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[47]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Syndrome of inappropriate antidiuretic hormone\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"vinorelbine\"]], \"start\": [[63]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"vinorelbine\"]], \"start\": [[63]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
18453852_14 | The study showed a high incidence of adverse events when a higher than standard dose of the new lopinavir/ritonavir tablets was combined with rifampicin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"when\"]], \"start\": [[52]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"higher than standard dose of the new lopinavir/ritonavir tablets was combined with rifampicin\"]], \"start\": [[59]], \"entity_id\": [\"T6\"], \"Dosage\": {\"text\": [[\"higher than standard dose\"]], \"start\": [[59]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"rifampicin\"], [\"lopinavir\"], [\"ritonavir\"]], \"start\": [[142], [96], [106]], \"entity_id\": [\"T11\", \"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combined\"]], \"start\": [[128]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"ritonavir\"], [\"lopinavir\"], [\"rifampicin\"]], \"start\": [[106], [96], [142]], \"entity_id\": [\"T13\", \"T12\", \"T11\"]}}]}, \"Effect\": {\"text\": [[\"adverse events\"]], \"start\": [[37]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
19499966_3 | Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"Onset\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"gynaecomastia\"]], \"start\": [[14]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"male\", \"a patient\"]], \"start\": [[9, 31]], \"entity_id\": [\"T4\"], \"Gender\": {\"text\": [[\"male\"]], \"start\": [[9]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"sunitinib for metastatic renal cell carcinoma\"]], \"start\": [[54]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"metastatic renal cell carcinoma\"]], \"start\": [[68]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"sunitinib\"]], \"start\": [[54]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
7973922_3 | Systemic disease, most commonly renal dysfunction, preceded all 30 reported cases of acyclovir neurotoxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"preceded\"]], \"start\": [[51]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"acyclovir\"]], \"start\": [[85]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"acyclovir\"]], \"start\": [[85]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Systemic disease, most commonly renal dysfunction\", \"neurotoxicity\"]], \"start\": [[0, 95]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"30 reported cases\"]], \"start\": [[64]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"30\"]], \"start\": [[64]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
4082283_1 | Rifampicin-induced renal failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Rifampicin\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Rifampicin\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"renal failure\"]], \"start\": [[19]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
15920338_1 | A case of high-grade endometrial stromal sarcoma, confined into an intrauterine polypoid growth, in a woman with a history of breast cancer who was treated with adjuvant tamoxifen. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[148]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"adjuvant tamoxifen\"]], \"start\": [[161]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"tamoxifen\"]], \"start\": [[170]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"high-grade endometrial stromal sarcoma, confined into an intrauterine polypoid growth\"]], \"start\": [[10]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"A case of high-grade endometrial stromal sarcoma, confined into an intrauterine polypoid growth, in a woman with a history of breast cancer\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[102]], \"entity_id\": [\"T6\"]}, \"Disorder\": {\"text\": [[\"breast cancer\"]], \"start\": [[126]], \"entity_id\": [\"T9\"]}, \"Population\": {\"text\": [[\"A\"]], \"start\": [[0]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
8880251_1 | After therapy for diabetic coma with insulin (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and lost consciousness. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"After\"]], \"start\": [[0]], \"entity_id\": [\"T14\"]}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[121]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"therapy for diabetic coma with insulin (containing the preservative cresol) and electrolyte solutions\"]], \"start\": [[6]], \"entity_id\": [\"T15\"], \"Disorder\": {\"text\": [[\"diabetic coma\"]], \"start\": [[18]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"insulin\"], [\"preservative cresol\"], [\"electrolyte solutions\"]], \"start\": [[37], [61], [86]], \"entity_id\": [\"T18\", \"T19\", \"T20\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[82]], \"entity_id\": [\"T21\"]}, \"Drug\": {\"text\": [[\"electrolyte solutions\"], [\"preservative cresol\"], [\"insulin\"]], \"start\": [[86], [61], [37]], \"entity_id\": [\"T20\", \"T19\", \"T18\"]}}]}, \"Effect\": {\"text\": [[\"increasing myalgia, developed a high fever and respiratory and metabolic acidosis and lost consciousness\"]], \"start\": [[147]], \"entity_id\": [\"T16\"]}}"
}
]
}
] |
19018868_1 | A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary\"]], \"start\": [[33]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"severe aplastic anemia\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A case\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"lenalidomide for multiple myeloma\"]], \"start\": [[61]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"multiple myeloma\"]], \"start\": [[78]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"lenalidomide\"]], \"start\": [[61]], \"entity_id\": [\"T9\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[10]], \"entity_id\": [\"T8\"], \"value\": \"Medium\"}}"
}
]
}
] |
21712512_5 | Seven weeks after the initiation of inhaled fluticasone, she developed vaginal candidiasis and was prescribed fluconazole 100 mg/day, a CYP3A4 inhibitor. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[61]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Seven weeks after the initiation of inhaled fluticasone\"]], \"start\": [[0]], \"entity_id\": [\"T10\"], \"Route\": {\"text\": [[\"inhaled\"]], \"start\": [[36]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"fluticasone\"]], \"start\": [[44]], \"entity_id\": [\"T12\"]}, \"Time_elapsed\": {\"text\": [[\"Seven weeks\"]], \"start\": [[0]], \"entity_id\": [\"T18\"]}}, \"Effect\": {\"text\": [[\"vaginal candidiasis\"]], \"start\": [[71]], \"entity_id\": [\"T9\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"prescribed\"]], \"start\": [[99]], \"entity_id\": [\"T20\"]}, \"Treatment\": {\"text\": [[\"fluconazole 100 mg/day, a CYP3A4 inhibitor\"]], \"start\": [[110]], \"entity_id\": [\"T21\"], \"Disorder\": {\"text\": [[\"vaginal candidiasis\"]], \"start\": [[71]], \"entity_id\": [\"T19\"]}, \"Drug\": {\"text\": [[\"fluconazole\"]], \"start\": [[110]], \"entity_id\": [\"T13\"]}, \"Dosage\": {\"text\": [[\"100 mg/day\"]], \"start\": [[122]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
7393795_4 | The introduction of para-aminosalicylic acid (PAS) led to hypoglycaemic coma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"led to\"]], \"start\": [[51]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"The introduction of para-aminosalicylic acid (PAS)\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"para-aminosalicylic acid\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"hypoglycaemic coma\"]], \"start\": [[58]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19434733_2 | The risk of developing sAML is estimated to be between 1% and 5%, 2-20 years after exposure to etoposide but may also be related to cumulative drug doses, treatment schedules, host factors and co-administration of other antineoplastic agents. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[77]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"sAML\"]], \"start\": [[23]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"2-20 years after exposure to etoposide\"]], \"start\": [[66]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"etoposide\"]], \"start\": [[95]], \"entity_id\": [\"T7\"]}, \"Time_elapsed\": {\"text\": [[\"2-20 years\"]], \"start\": [[66]], \"entity_id\": [\"T8\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[109]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
3688031_1 | An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and propranolol. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[172]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"methimazole and propranolo\"]], \"start\": [[177]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"methimazole\"], [\"propranolol\"]], \"start\": [[177], [193]], \"entity_id\": [\"T16\", \"T18\"]}, \"Disorder\": {\"text\": [[\"hyperthyroidism\"]], \"start\": [[135]], \"entity_id\": [\"T17\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[189]], \"entity_id\": [\"T19\"]}, \"Drug\": {\"text\": [[\"methimazole\"], [\"propranolol\"]], \"start\": [[177], [193]], \"entity_id\": [\"T16\", \"T18\"]}}]}, \"Effect\": {\"text\": [[\"An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate mental retardation\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"a woman\"]], \"start\": [[115]], \"entity_id\": [\"T1\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[117]], \"entity_id\": [\"T2\"]}}}"
}
]
}
] |
2956288_1 | Ethambutol is frequently used in the treatment of tuberculosis, and, although optic neuropathies have been reported with the use of ethambutol, this adverse side effect has been considered to be rare and generally reversible with discontinuation of the medication. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"used\"]], \"start\": [[25]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Ethambutol\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"tuberculosis\"]], \"start\": [[50]], \"entity_id\": [\"T4\"]}, \"Drug\": {\"text\": [[\"Ethambutol\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
10923593_1 | Skin manifestations of a case of phenylbutazone-induced serum sickness-like reactions. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[48]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"phenylbutazone\"]], \"start\": [[33]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"phenylbutazone\"]], \"start\": [[33]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"serum sickness-like reactions\"]], \"start\": [[56]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
18607107_2 | Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"Development\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"copaxone\"]], \"start\": [[81]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"multiple sclerosis\"]], \"start\": [[49]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"copaxone\"]], \"start\": [[81]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Crohn's disease\"]], \"start\": [[15]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a patient with multiple sclerosis\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19281746_1 | Aliskiren-associated acute renal failure with hyperkalemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[10]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Aliskiren\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Aliskiren\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"acute renal failure\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
7752014_3 | Fever caused by the use of furosemide was proved; the fever resolved after discontinuation of this medication and recurred after its reintroduction. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[6]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Fever\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"furosemide\"]], \"start\": [[27]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"furosemide\"]], \"start\": [[27]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
8034807_1 | The use of methotrexate (MTX) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"accelerate\"]], \"start\": [[217]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"MTX\"]], \"start\": [[161]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"methotrexate (MTX)\"], [\"MTX\"]], \"start\": [[11], [161]], \"entity_id\": [\"T8\", \"T9\"]}}, \"Effect\": {\"text\": [[\"HIV disease\"]], \"start\": [[228]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
17655376_1 | Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[44]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"dapsone gel, 5%\"]], \"start\": [[20]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"dapsone\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"acne vulgaris\"]], \"start\": [[57]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
19183077_2 | To our knowledge, these cases represent the first reports of TDF-associated irreversible renal failure and rickets in pediatric patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[65]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"TDF\"]], \"start\": [[61]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"TDF\"]], \"start\": [[61]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"irreversible renal failure and rickets\"]], \"start\": [[76]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"pediatric patients\"]], \"start\": [[118]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"pediatric\"]], \"start\": [[118]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
7781845_4 | In particular, this adverse effect has never been described with mefloquine (Lariam). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"described\"]], \"start\": [[50]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"mefloquine (Lariam)\"]], \"start\": [[65]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"mefloquine\"]], \"start\": [[65]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"adverse effect\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}, \"Negated\": {\"text\": [[\"never\"]], \"start\": [[39]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
8949576_1 | A potential role for renal and hepatic impairment in the observed protracted course of amiodarone-induced thyrotoxicosis is suggested. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[98]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[87]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[87]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"thyrotoxicosis\"]], \"start\": [[106]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"potential\"]], \"start\": [[2]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
18691992_7 | The patient completed a 10-month follow-up, maintaining a complete resolution of the treated skin lesions; however, the development of a painful hand ulcer, possibly associated with the hydroxyurea, and new skin cancers were observed at the last follow-up visit. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[166]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"The patient\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"a painful hand ulcer\", \"new skin cancers\"]], \"start\": [[135, 203]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"hydroxyurea\"]], \"start\": [[186]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"skin lesions\"]], \"start\": [[93]], \"entity_id\": [\"T6\"]}, \"Duration\": {\"text\": [[\"10-month\"]], \"start\": [[24]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"hydroxyurea\"]], \"start\": [[186]], \"entity_id\": [\"T11\"]}}, \"Speculated\": {\"text\": [[\"possibly\"]], \"start\": [[157]], \"entity_id\": [\"T12\"], \"value\": true}}"
}
]
}
] |
17420198_1 | Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"mediated\"]], \"start\": [[23]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"aripiprazole\"]], \"start\": [[10]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"aripiprazole\"]], \"start\": [[10]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"developmental disabilities\"]], \"start\": [[73]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"extrapyramidal symptoms\"]], \"start\": [[32]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"an adult with developmental disabilities\"]], \"start\": [[59]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"adult\"]], \"start\": [[62]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
12823045_1 | We describe a patient with extranodal non-Hodgkin lymphoma who developed systemic candidiasis after treatment with a cyclophosphamide-based chemotherapy regimen. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[100]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient with extranodal non-Hodgkin lymphoma\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"systemic candidiasis\"]], \"start\": [[73]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"a cyclophosphamide-based chemotherapy regimen.\"]], \"start\": [[115]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"extranodal non-Hodgkin lymphoma\"]], \"start\": [[27]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"cyclophosphamide-based chemotherapy\"]], \"start\": [[117]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
2663536_2 | We describe the first case of de novo asthma following treatment with the angiotensin converting enzyme (ACE) inhibitor captopril. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treatment with\"]], \"start\": [[55]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"de novo asthma\"]], \"start\": [[30]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"the angiotensin converting enzyme (ACE) inhibitor captopril\"]], \"start\": [[70]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"captopril\"]], \"start\": [[120]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
8120934_1 | A 53-year-old male, without any prior history of psychosis, developed schizophrenia 4 days after starting low-dose bromocriptine therapy for a macroprolactinoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[60]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"A 53-year-old male, without any prior history of psychosis\", \"macroprolactinoma\"]], \"start\": [[0, 143]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"53-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[14]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"schizophrenia\"]], \"start\": [[70]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"4 days after starting low-dose bromocriptine therapy\"]], \"start\": [[84]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"bromocriptine\"]], \"start\": [[115]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"macroprolactinoma\"]], \"start\": [[143]], \"entity_id\": [\"T11\"]}, \"Time_elapsed\": {\"text\": [[\"4 days after\"]], \"start\": [[84]], \"entity_id\": [\"T12\"]}, \"Dosage\": {\"text\": [[\"low-dose\"]], \"start\": [[106]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
20298401_7 | Six days after taking erlotinib, a chest radiograph showed rapid progression of reticular infiltration in both lung fields. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[9]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"rapid progression of reticular infiltration in both lung fields\"]], \"start\": [[59]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Six days\", \"erlotinib\"]], \"start\": [[0, 22]], \"entity_id\": [\"T5\"], \"Time_elapsed\": {\"text\": [[\"Six days\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"erlotinib\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
11144696_6 | Because of suspected drug-induced seizures, both antidepressants were stopped. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"stopped\"]], \"start\": [[70]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"antidepressants\"]], \"start\": [[49]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"antidepressants\"]], \"start\": [[49]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"seizures\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"suspected\"]], \"start\": [[11]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
17381671_4 | Based on the Naranjo probability scale, serotonin syndrome was a probable adverse reaction associated with co-administration of citalopram and fentanyl. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[91]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[40]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"co-administration of citalopram and fentanyl\"]], \"start\": [[107]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"citalopram\"], [\"fentanyl\"]], \"start\": [[128], [143]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"co-administration\"]], \"start\": [[107]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"citalopram\"], [\"fentanyl\"]], \"start\": [[128], [143]], \"entity_id\": [\"T10\", \"T11\"]}}]}, \"Speculated\": {\"text\": [[\"probable\"]], \"start\": [[65]], \"entity_id\": [\"T13\"], \"value\": true}}"
}
]
}
] |
18034202_1 | We report a case of a patient with rheumatoid arthritis treated with low-dose methotrexate (15 mg/week) who developed infection with both M. tuberculosis and M. chelonae after the revision of a prosthetic hip. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[108]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"patient with rheumatoid arthritis\"]], \"start\": [[22]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"low-dose methotrexate (15 mg/week)\"]], \"start\": [[69]], \"entity_id\": [\"T5\"], \"Dosage\": {\"text\": [[\"15 mg/week\"]], \"start\": [[92]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[78]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[35]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"nfection with both M. tuberculosis and M. chelonae\"]], \"start\": [[119]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
10575189_2 | Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"undergoing\"]], \"start\": [[62]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"gemcitabine chemotherapy\"]], \"start\": [[73]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"gemcitabine\"]], \"start\": [[73]], \"entity_id\": [\"T10\"]}, \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[85]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"Thrombotic microangiopathy with renal failure\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"two patients\"]], \"start\": [[49]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[49]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
8771575_3 | Despite the known pulmonary side effects of nitrofurantoin, there is no report of this toxicity occurring in pregnant patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"of\"]], \"start\": [[41]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"pulmonary side effects\"]], \"start\": [[18]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"nitrofurantoin\"]], \"start\": [[44]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"nitrofurantoin\"]], \"start\": [[44]], \"entity_id\": [\"T6\"]}}, \"Negated\": {\"text\": [[\"no\"]], \"start\": [[69]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
19995222_3 | However, several case reports have suggested that clozapine could also cause TD. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[71]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"TD\"]], \"start\": [[77]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"clozapine\"]], \"start\": [[50]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"clozapine\"]], \"start\": [[50]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
2862137_1 | A case is presented in which a 68-year-old man became delirious after being withdrawn from a low dosage of alprazolam. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[64]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"68-year-old man\"]], \"start\": [[31]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"68-year-old\"]], \"start\": [[31]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[43]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"withdrawn from a low dosage of alprazolam\"]], \"start\": [[76]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"alprazolam\"]], \"start\": [[107]], \"entity_id\": [\"T9\"]}, \"Dosage\": {\"text\": [[\"low dosage\"]], \"start\": [[93]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"delirious\"]], \"start\": [[54]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
19499966_2 | However, re-initiation of sunitinib treatment was followed by bilateral breast enlargement again. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"followed\"]], \"start\": [[50]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"sunitinib\"]], \"start\": [[26]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"sunitinib\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"bilateral breast enlargement\"]], \"start\": [[62]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
18691992_1 | BACKGROUND: Hydroxyurea is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with mucocutaneous adverse events and nail hyperpigmentation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[116]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Hydroxyurea is a cytostatic agen\"]], \"start\": [[12]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Hydroxyurea\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"myeloproliferative disorders\"]], \"start\": [[60]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"mucocutaneous adverse events and nail hyperpigmentation\"]], \"start\": [[132]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
6353252_1 | Captopril-induced acute reversible renal failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Captopril\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Captopril\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"acute reversible renal failure\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16498048_3 | Hence, hyperthyroidism induced by IFN-alpha could correspond to the first phase of silent thyroiditis, to Graves' disease or to the succession of both. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"IFN-alpha\"]], \"start\": [[34]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"IFN-alpha\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hyperthyroidism\"]], \"start\": [[7]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12107858_1 | The epivodes of NMS occured under treatment with clozapine, risperidone, and amisulpride. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occured\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"NMS\"]], \"start\": [[16]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"clozapine, risperidone, and amisulpride\"]], \"start\": [[49]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"clozapine\"], [\"risperidone\"], [\"amisulpride\"]], \"start\": [[49], [60], [77]], \"entity_id\": [\"T8\", \"T9\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[73]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"clozapine\"], [\"risperidone\"], [\"amisulpride\"]], \"start\": [[49], [60], [77]], \"entity_id\": [\"T8\", \"T9\", \"T11\"]}}]}}"
}
]
}
] |
10466445_8 | During the first days of arsenic trioxide treatment a rapid decrease in the D-dimers was seen (normal values reached until day 7), together with a slight decrease in peripheral blood leukocytes. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"During\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"the first days of arsenic trioxide treatment\"]], \"start\": [[7]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"arsenic trioxide\"]], \"start\": [[25]], \"entity_id\": [\"T8\"]}, \"Duration\": {\"text\": [[\"the first days\"]], \"start\": [[7]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"a rapid decrease in the D-dimers was seen (normal values reached until day 7), together with a slight decrease in peripheral blood leukocytes\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19104709_2 | In contrast to chronic or subacute thyroiditis, Graves' disease rarely complicates IFN-alpha therapy for chronic viral C hepatitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"for\"]], \"start\": [[101]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"IFN-alpha\"]], \"start\": [[83]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"chronic viral C hepatitis\"]], \"start\": [[105]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"IFN-alpha\"]], \"start\": [[83]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"Graves' disease\"]], \"start\": [[48]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"Graves' disease\"]], \"start\": [[48]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
17551408_1 | We postulate that gastritis caused by dexamethasone, mucositis caused by doxorubicin, and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[28]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"gastritis\"]], \"start\": [[18]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"dexamethasone\"]], \"start\": [[38]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"dexamethasone\"]], \"start\": [[38]], \"entity_id\": [\"T9\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[142]], \"entity_id\": [\"T8\"], \"value\": true}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[63]], \"entity_id\": [\"T12\"]}, \"Effect\": {\"text\": [[\"mucositis\"]], \"start\": [[53]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"doxorubicin\"]], \"start\": [[73]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"doxorubicin\"]], \"start\": [[73]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
9013348_3 | Mesalamine may cause hypersensitivity pneumonitis in patients with Crohn's disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[15]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Mesalamine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"Crohn's disease\"]], \"start\": [[67]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"Mesalamine\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity pneumonitis\"]], \"start\": [[21]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients with Crohn's disease\"]], \"start\": [[53]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[11]], \"entity_id\": [\"T4\"], \"value\": true}}"
}
]
}
] |
7814182_2 | We present a case in which dipyridamole induced high-grade atrioventricular (AV) block that responded promptly to intravenous aminophylline but not to atropine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[40]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"dipyridamole\"]], \"start\": [[27]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"dipyridamole\"]], \"start\": [[27]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"high-grade atrioventricular (AV) block\"]], \"start\": [[48]], \"entity_id\": [\"T5\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"responded\"]], \"start\": [[92]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"intravenous aminophylline but not to atropine\"]], \"start\": [[114]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"intravenous aminophylline\"], [\"atropine\"]], \"start\": [[114], [151]], \"entity_id\": [\"T11\", \"T12\"]}, \"Disorder\": {\"text\": [[\"dipyridamole induced high-grade atrioventricular (AV) block\"]], \"start\": [[27]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
2442958_3 | This paper reports an autopsy case of a 78-year-old male with multiple nodules in the liver developed after long-termed administration of phosphate diethylstilbestrol (PDES) for prostatic cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[92]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"an autopsy case of a 78-year-old male\", \"prostatic cancer\"]], \"start\": [[19, 178]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"78-year-old\"]], \"start\": [[40]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[52]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"multiple nodules in the liver\"]], \"start\": [[62]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"phosphate diethylstilbestrol (PDES)\"]], \"start\": [[138]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"prostatic cancer\"]], \"start\": [[178]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"phosphate diethylstilbestrol\"]], \"start\": [[138]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
7933665_1 | Fracture of the femoral neck occurred in one patient during PSL therapy, although the relationship between the fracture and PSL therapy was uncertain. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[29]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Fracture of the femoral neck\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"one patient\"]], \"start\": [[41]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"one\"]], \"start\": [[41]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"PSL therapy\"]], \"start\": [[60]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"PSL\"]], \"start\": [[60]], \"entity_id\": [\"T9\"]}}, \"Speculated\": {\"text\": [[\"uncertain\"]], \"start\": [[140]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |